The introduction of new drugs has steadily improved the prognosis of patients with multiple myeloma over the past years. Diagnostics have also been expanded, in particular by cytogenetic analyses, which allow a more precise risk stratification. Nevertheless, the 5-year survival rate in stage III is only 40%, so there is still room for innovation.